miR-29 is a major regulator of genes associated with pulmonary fibrosis.

MicroRNAs (miRNA) are small regulatory RNAs that control gene expression by translational suppression and destabilization of target mRNAs. There is increasing evidence that miRNAs regulate genes associated with fibrosis in organs, such as the heart, kidney, liver, and the lung. In a large-scale screening for miRNAs potentially involved in bleomycin-induced fibrosis, we found expression of miR-29 family members significantly reduced in fibrotic lungs. Analysis of normal lungs showed the presence of miR-29 in subsets of interstitial cells of the alveolar wall, pleura, and at the entrance of the alveolar duct, known sites of pulmonary fibrosis. miR-29 levels inversely correlated with the expression levels of profibrotic target genes and the severity of the fibrosis. To study the impact of miR-29 down-regulation in the lung interstitium, we characterized gene expression profiles of human fetal lung fibroblast IMR-90 cells in which endogenous miR-29 was knocked down. This confirmed the derepression of reported miR-29 targets, including several collagens, but also revealed up-regulation of a large number of previously unrecognized extracellular matrix-associated and remodeling genes. Moreover, we found that miR-29 is suppressed by transforming growth factor (TGF)-β1 in these cells, and that many fibrosis-associated genes up-regulated by TGF-β1 are derepressed by miR-29 knockdown. Interestingly, a comparison of TGF-β1 and miR-29 targets revealed that miR-29 controls an additional subset of fibrosis-related genes, including laminins and integrins, independent of TGF-β1. Together, these strongly suggest a role of miR-29 in the pathogenesis of pulmonary fibrosis. miR-29 may be a potential new therapeutic target for this disease.

[1]  N. Kaminski,et al.  miR-21 mediates fibrogenic activation of pulmonary fibroblasts and lung fibrosis , 2010, The Journal of experimental medicine.

[2]  Xiao-ming Meng,et al.  miR-192 mediates TGF-beta/Smad3-driven renal fibrosis. , 2010, Journal of the American Society of Nephrology : JASN.

[3]  Oliver Eickelberg,et al.  Inhibition and role of let-7d in idiopathic pulmonary fibrosis. , 2010, American journal of respiratory and critical care medicine.

[4]  Oliver Distler,et al.  MicroRNA-29, a key regulator of collagen expression in systemic sclerosis. , 2010, Arthritis and rheumatism.

[5]  J. Mattick,et al.  Non‐coding RNAs: regulators of disease , 2010, The Journal of pathology.

[6]  R. Strieter,et al.  New mechanisms of pulmonary fibrosis. , 2009, Chest.

[7]  David Julius,et al.  Cellular and Molecular Mechanisms of Pain , 2009, Cell.

[8]  Kristina Kapinas,et al.  miR‐29 suppression of osteonectin in osteoblasts: Regulation during differentiation and by canonical Wnt signaling , 2009, Journal of cellular biochemistry.

[9]  G. Jenkins,et al.  Role of integrin-mediated TGFbeta activation in the pathogenesis of pulmonary fibrosis. , 2009, Biochemical Society transactions.

[10]  K. Zatloukal,et al.  miR‐29a suppresses tristetraprolin, which is a regulator of epithelial polarity and metastasis , 2009, EMBO reports.

[11]  D. Bartel.  MicroRNAs: Target Recognition and Regulatory Functions , 2009, Cell.

[12]  W. Rottbauer,et al.  MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts , 2008, Nature.

[13]  Huating Wang,et al.  NF-kappaB-YY1-miR-29 regulatory circuitry in skeletal myogenesis and rhabdomyosarcoma. , 2008, Cancer cell.

[14]  J. Friedman,et al.  A role for microRNA in cystic liver and kidney diseases. , 2008, The Journal of clinical investigation.

[15]  Domenico Coppola,et al.  MicroRNA-155 Is Regulated by the Transforming Growth Factor β/Smad Pathway and Contributes to Epithelial Cell Plasticity by Targeting RhoA , 2008, Molecular and Cellular Biology.

[16]  E. Bradley,et al.  TGF-beta coordinately activates TAK1/MEK/AKT/NFkB and SMAD pathways to promote osteoclast survival. , 2008, Experimental cell research.

[17]  Jeffrey E. Thatcher,et al.  Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis , 2008, Proceedings of the National Academy of Sciences.

[18]  Paul Ahlquist,et al.  MicroRNA 29c is down-regulated in nasopharyngeal carcinomas, up-regulating mRNAs encoding extracellular matrix proteins , 2008, Proceedings of the National Academy of Sciences.

[19]  W. Schiemann,et al.  Altered TAB1:I kappaB kinase interaction promotes transforming growth factor beta-mediated nuclear factor-kappaB activation during breast cancer progression. , 2008, Cancer research.

[20]  C. Hogaboam,et al.  Murine models of pulmonary fibrosis. , 2008, American journal of physiology. Lung cellular and molecular physiology.

[21]  G. Laurent,et al.  Idiopathic pulmonary fibrosis: multiple causes and multiple mechanisms? , 2007, European Respiratory Journal.

[22]  E. Olson,et al.  MicroRNAs: powerful new regulators of heart disease and provocative therapeutic targets. , 2007, The Journal of clinical investigation.

[23]  Mattias Alenius,et al.  Locked nucleic acid-based in situ detection of microRNAs in mouse tissue sections , 2007, Nature Protocols.

[24]  F Verrecchia,et al.  [Cellular and molecular mechanisms of fibrosis]. , 2006, Annales de pathologie.

[25]  C. Croce,et al.  MicroRNA-cancer connection: the beginning of a new tale. , 2006, Cancer research.

[26]  M. Selman,et al.  Matrix metalloproteases in aberrant fibrotic tissue remodeling. , 2006, Proceedings of the American Thoracic Society.

[27]  A. Stewart,et al.  Extracellular matrix, integrins, and mesenchymal cell function in the airways. , 2006, Current drug targets.

[28]  M. Hallett,et al.  Murine candidate bleomycin induced pulmonary fibrosis susceptibility genes identified by gene expression and sequence analysis of linkage regions , 2005, Journal of Medical Genetics.

[29]  S. Thorgeirsson,et al.  Transient activation of NF-κB through a TAK1/IKK kinase pathway by TGF-β1 inhibits AP-1/SMAD signaling and apoptosis: implications in liver tumor formation , 2003, Oncogene.

[30]  D. Warburton,et al.  Smad3 deficiency attenuates bleomycin-induced pulmonary fibrosis in mice. , 2002, American journal of physiology. Lung cellular and molecular physiology.

[31]  C. Lisboa,et al.  Bleomycin-induced chronic lung damage does not resemble human idiopathic pulmonary fibrosis. , 2001, American journal of respiratory and critical care medicine.

[32]  J. Romashkova,et al.  NF-κB is a target of AKT in anti-apoptotic PDGF signalling , 1999, Nature.

[33]  J. Romashkova,et al.  NF-kappaB is a target of AKT in anti-apoptotic PDGF signalling. , 1999, Nature.

[34]  K. Csaky,et al.  Adenovector-mediated gene transfer of active transforming growth factor-beta1 induces prolonged severe fibrosis in rat lung. , 1997, The Journal of clinical investigation.

[35]  T. Colby,et al.  Transforming growth factor beta 1 is present at sites of extracellular matrix gene expression in human pulmonary fibrosis. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[36]  J. Lazo,et al.  Bleomycin: a pharmacologic tool in the study of the pathogenesis of interstitial pulmonary fibrosis. , 1990, Pharmacology & therapeutics.

[37]  A. Kang,et al.  Coordinate regulation of transforming growth factor beta gene expression and cell proliferation in hamster lungs undergoing bleomycin-induced pulmonary fibrosis. , 1989, The Journal of clinical investigation.

[38]  F. Askin,et al.  Nodular form of bleomycin‐related pulmonary injury in patients with osteogenic sarcoma , 1989, Cancer.

[39]  R. Crystal,et al.  Collagen in the human lung. Quantitation of rates of synthesis and partial characterization of composition. , 1975, The Journal of clinical investigation.